MdxHealth (TM) : MDxHealth Signs Agreement with Stratose® to Expand Insurance Coverage for ConfirmMDxTM for Prostate Cancer

MdxHealth (TM) : MDxHealth Signs Agreement with Stratose® to Expand Insurance
              Coverage for ConfirmMDxTM for Prostate Cancer Test

IRVINE, CA, and  HERSTAL, BELGIUM --  September 3, 2013  - MDxHealth SA  (NYSE 
Euronext: MDXH),  a leading  molecular diagnostic  company that  develops  and 
commercializes epigenetic  tests to  support the  diagnosis and  treatment  of 
cancer patients, today announced  that it has entered  into an agreement  with 
Stratose, one of the largest healthcare PPO network providers in the U.S.  The 
agreement provides  Stratose's  12.4 million  member  network with  access  to 
ConfirmMDx for Prostate Cancer testing.

ConfirmMDx for Prostate Cancer provides  urologists and their patients with  a 
non-invasive approach  to address  false-negative  biopsy concerns.  The  test 
provides urologists with  actionable information  on the  decision for  repeat 
biopsy, aiding in the stratification of patients at sufficiently low risk  who 
may avoid repeat  biopsy and return  to screening,  from those who  may be  at 
increased risk for  harboring undetected  cancer, meriting  repeat biopsy  and 
potentially treatment. 

"MDxHealth continues  to work  with payers  and specialty  networks to  expand 
patient and  customer  access to  the  ConfirmMDx for  Prostate  Cancer  test. 
Stratose's network supplements  more than 90  different third-party  insurance 
payers. Since 70% of all MDxHealth  ConfirmMDx cases are billed to  commercial 
and third-party  payers, these  contracts are  very important,"  said Dr.  Jan 
Groen, CEO of MDxHealth. "With the addition of Stratose to our existing  payer 
agreements, more than 80 million covered  lives now have access to  ConfirmMDx 
for Prostate Cancer."

Stratose (formerly  operating  as  Coalition  America,  NPPN,  OPPN,  PlanCare 
America, 4MOST Health, Qualident and KeyClaims)  works to reduce the cost  and 
ensure the  best  financial results  on  every medical,  dental  and  workers' 
compensation claim for  any claims  payer. The  company maintains  one of  the 
largest directly managed PPO networks in the U.S., including more than 850,000
direct and  affiliate  medical,  dental  and  workers'  compensation  provider 
contracts.

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of  patients.  The  company's  first  commercial  product,  ConfirmMDx^TM  for 
Prostate Cancer,  has been  shown  to help  distinguish  patients who  have  a 
true-negative biopsy  from those  who may  have undetected  cancer.  MDxHealth 
helps to address  a large  and growing unmet  medical need  for better  cancer 
diagnosis and treatment  information. The company  has a proprietary  platform 
and a  strong  epigenetic  product  pipeline focused  on  the  development  of 
products for prostate, brain and lung cancers. The company is based in Irvine,
California  with  a  European  headquarters  in  Herstal,  Belgium.  For  more 
information visit MDxHealth's website at www.mdxhealth.com.

For more information:

Dr. Jan Groen, CEO Mike Sinclair         Matt Clawson
MDxHealth                      Halsin Partners        Allen & Caron, Inc
US: +1 949 812 6979            UK: +44 20 7318 2955  US: +1 949 474 4300
BE: +32 43642070 Cell:+44 7968 022075 
info@mdxhealth.com            msinclair@halsin.com   matt@allencaron.com



This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.



NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

To access the PDF version, please click here

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1726660